Creative Medical Technology Holdings Inc. has announced the successful completion of patient enrollment in its FDA-cleared ADAPT clinical trial for CELZ-201 (Olastrocel), a proprietary perinatal tissue-derived cell therapy targeting chronic lower back pain associated with degenerative disc disease. The company reported that a positive safety review by an independent Data Safety Monitoring Board found no significant adverse events, supporting the continued advancement of the trial. Topline safety and efficacy results have not yet been presented and are expected in the future as the company advances toward later-stage development and potential commercialization.